Systemic Antibiotics for Pseudomonas Aeruginosa Infection in Outpatients with Lung Diseases: Clinical Trial Results
Background
The study aimed to determine the impact of dual systemic antibiotic therapy on Pseudomonas aeruginosa in outpatients with COPD, non-CF bronchiectasis, or asthma.
Methods
The trial was conducted at seven respiratory outpatient clinics in Denmark. Outpatients with pre-existing lung diseases and P. aeruginosa-positive lower respiratory tract culture were eligible. They were assigned to receive 14 days of dual systemic anti-pseudomonal antibiotics or no antibiotic treatment.
Results
The trial was stopped prematurely due to lack of recruitment during the COVID-19 pandemic. However, the antibiotic group showed a reduced risk of exacerbation or death compared to the control group. The use of dual systemic antibiotics improved clinical outcomes in outpatients with chronic lung diseases and no need for hospitalization.
Conclusions
Using dual systemic antibiotics for 14 days against P. aeruginosa in outpatients with chronic lung diseases improved clinical outcomes significantly. The main limitation was the premature closure of the trial.
Trial Registration
ClinicalTrials.gov, NCT03262142, registration date 2017-08-25.
Clinical Trials and AI-Driven Solutions
Clinical trials play a crucial role in developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates ICD-11 standards, clinical protocols, and research into a single, easily accessible knowledge base for clinicians.
Streamlining Healthcare Operations with AI
In today’s healthcare environment, streamlining operations is crucial. Our mobile apps support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally.
Enhancing Workflows and Patient Outcomes with AI
By using AI, clinics can enhance their workflows and improve patient outcomes, reducing paper routine. Learn more about how we can help at aidevmd.com.
